MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Dispatch Biotherapeutics
Organization & Developments: Dispatch Biotherapeutics
Parents
Dispatch Biotherapeutics
Children
* Developing therapies that kill cancer tumors and do not let them relapse
*Cancer therapies that harness the immune system.
*Dispatch uses an engineered virus to seek out cancerous cells and tag them with what it refers to as a “flare.” This flare is an antigen that a CAR-T therapy subsequently administered is designed to seek out.
*Dispatch’s work is based on research from University of Pennsylvania cell therapy pioneer Carl June, Stanford University professor Chris Garcia, University of California, San Francisco professor Kole Roybal, and Memorial Sloan Kettering Cancer Center new chair of immuno-oncology Andy Minn.
*Formed in 2022 through a collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy and built around technologies from scientific labs in Pennsylvania and California.
2025: Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy
Jumps
Finance & Acquisition: Dispatch Biotherapeutics
Key People: Dispatch Biotherapeutics